Table 2.

Colorectal cancer-specific mortality and overall mortality according to MIC1 levels.

	Quartile of plasma MIC1a
Analysis	1	2	3	4	Ptrendb
All-cause mortality (n=618)
No. of events/No. at risk	25/119	62/160	83/174	96/165
Age-adjusted HR (95% CI)	1 (referent)	1.88 (1.17–3.03)	2.51 (1.57–3.99)	2.85 (1.78–4.58)	<0.0001
MV-adjusted HR (95% CI)c	1 (referent)	1.77 (1.07–2.91)	2.55 (1.55–4.19)	2.63 (1.60–4.32)	0.0002
MV-adjusted HR (95% CI)d	1 (referent)	1.74 (1.06–2.88)	2.54 (1.54–4.19)	2.63 (1.60–4.32)	0.0002
CRC-specific mortality (n=618)
No. of events/No. at risk	19/119	43/160	59/174	57/165
Age-adjusted HR (95% CI)	1 (referent)	1.94 (1.12–3.37)	2.64 (1.54–4.51)	2.73 (1.57–4.75)	0.003
MV-adjusted HR (95% CI)c	1 (referent)	1.65 (0.92–2.94)	2.60 (1.45–4.67)	2.34 (1.30–4.21)	0.01
MV-adjusted HR (95% CI)d	1 (referent)	1.67 (0.93–3.00)	2.67 (1.49–4.80)	2.40 (1.33–4.34)	0.009

^aQuartiles of plasma MIC1 were defined by the distribution among control individuals without CRC in our previous study.⁹ We assigned participants to quartile categories based upon cohort-specific cutpoints (NHS: Q1 <565; Q2 565–747, Q3 748–953, Q4 >953 pg/mL) (HPFS: Q1 <610; Q2 610–825; Q3 826–1060; Q4 >1060 pg/mL).

^bTests for linear trend were conducted using the median values for each quartile of MIC1.

^cAdditionally adjusted for the following potential confounders: cohort (sex); date of blood draw; race; body mass index (BMI) at the time of blood draw; physical activity (in MET-hours/week) at the time of blood draw; family history of CRC at time of blood draw; regular use of aspirin or NSAIDs at the time of blood draw; stage at diagnosis; history of polyps at the time of blood draw; grade (poor/unknown vs. well vs. moderate) at diagnosis; and anatomic tumor location (colon vs. rectum) at diagnosis

^dMultivariate models additionally adjusted for the plasma inflammatory markers CRP and IL6 as continuous measures as well as the factors listed in c